NMD4C Basic Science Trainee Committee Provides Leadership Opportunity for Next Generation of Neuromuscular Researchers
The NMD4C is excited to announce the nine members of the newly-formed Basic Science Trainee Committee! Representing the interests of trainees within the network, the BSTC offers an opportunity for professional growth for future leaders in neuromuscular research.
Committee Chair Dr Jean-Philippe Leduc-Gaudet shares “The formation of the Basic Science Trainee Committee is an exciting milestone for the NMD4C, providing important leadership opportunities for the next generation of neuromuscular researchers and strengthening the trainee voice within the network’s pre-clinical science activities. I look forward to working with this talented group of trainees to make a lasting impact in the Canadian neuromuscular research community.”
The group will work to communicate the training and professional development needs of trainees to the NMD4C pre-clinical science pillar leads, provide feedback, and suggest improvements to existing NMD4C trainee opportunities. Additionally, the BSTC will work on their own projects to strengthen the collaborative landscape of basic neuromuscular research resources in Canada, including:
- Creating an open-source database of research protocols and expertise from neuromuscular research labs in Canada.
- Implementing individual traineeships to learn specialized techniques.
- Supporting the organization of events, workshops, and activities geared towards trainees that promote professional and personal development.
The BSTC is composed of 9 members, including a chair, co-chair, secretary, and general members, reflective of the diversity of the neuromuscular trainee population in Canada
Meet the Team:
- Dr Jean-Philippe Leduc-Gaudet, Chair
- Dr Emma Sutton, Co-Chair
- Dr Adrien Rihoux, Secretary
- Shatha Atieh
- Jaryeon Lee
- Dr Sean Ng
- Dr Matthew Triolo
- Rebecca Yaworski
Read more about the team and their mandate.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.